ASTRO submits comments to CMS following April 2022 proposed rule to indefinitely delay RO Model

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

July 17, 2026

Vol.52 No.28

By Paul Goldberg and Claire Marie Porter

Cancer Policy

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Medicare Advantage beneficiaries have access to fewer cancer specialists, when compared to traditional Medicare beneficiaries, according to a study published in JAMA Network Open.

Equal access to cancer care removes race as predictor of survival, VA analysis finds

A healthcare system designed to provide more consistent access to comprehensive multidisciplinary cancer care can help eliminate longstanding racial gaps in cancer survival in the United States, according to a study led by a UCLA-VA collaborative team.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

Research has uncovered persistent disparities in preventive cancer care across different sexual orientation and gender identity populations. The study, conducted by researchers at The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, found particular concern for cervical and breast cancer screening.

July 10, 2026

Vol.52 No.27

Podcast The Directors

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.

June 26, 2026

Vol.52 No.25

By Paul Goldberg and Claire Marie Porter

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally.

June 05, 2026

Vol.52 No.22

By Claire Marie Porter

ASTRO submits comments to CMS following April 2022 proposed rule to indefinitely delay RO Model

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Equal access to cancer care removes race as predictor of survival, VA analysis finds

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

Renew today!

Subscriber content

Never miss an issue!

Login

ASTRO submits comments to CMS following April 2022 proposed rule to indefinitely delay RO Model

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

Equal access to cancer care removes race as predictor of survival, VA analysis finds

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas“Institutions are feeling crunched in so many different directions”

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

Never miss an issue!

Login

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas
“Institutions are feeling crunched in so many different directions”

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”